14.00 -0.09 (-0.64%)
After hours: 5:07PM EDT
|Bid||14.00 x 300|
|Ask||14.25 x 100|
|Day's Range||13.80 - 14.87|
|52 Week Range||8.36 - 27.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In case you missed it, here are some of Benzinga's top stories from Thursday, March 22, 2018. GameStop’s Turnaround Progress With GameStop Corp (NYSE: GME ) reporting its Q4 results next week, analysts ...
Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.
Extended Medicare reimbursement for Omeros Corporation (NASDAQ: OMER )’s OMIDRIA , along with the company’s increased focus on OMS721 trials, will act as solid short- and long-term drivers, according to ...
Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected. Still, Height Capital Markets analyst Andrea ...
Omeros Corp. shares surged 45% in extremely heavy morning trade Thursday on a new government spending bill that benefits its cataract surgery drug Omidria. Omidria's "pass-through" status with ...
Omeros Corporation’s (NASDAQ:OMER): Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. TheRead More...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Guess?, Inc. (NYSE: GES ) stock gained more than 11 ...
On a per-share basis, the Seattle-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring costs, came to 25 cents per share. The drug developer posted revenue of $13.8 million ...
Shares of drug maker Omeros Corporation (NASDAQ:OMER) are down 17% as of 3:53 p.m. EST today. In its report, FourWorld notes that Medicare, describing Omidria as a "nice-to-have" but not a "need-to-have" product, ended "pass-through" reimbursement for the drug as of January 1.
Omeros Corp. is the latest short target for FourWorld Capital Management LLC, as the investment adviser issues a new report on the drugmaker with a price target of $4.00, suggesting a more than 70 percent ...
Omeros shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Omeros Corporation (NASDAQ:OMER), a pharmaceuticals company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. With manyRead More...
This morning, the drug maker announced that it has reached an agreement with the FDA that available data from OMS721 supports the prospect for benefit in IgA nephropathy (IgAN) patients. Following the approval of the Phase 3 trial protocol, patient enrollment is expected to begin early next month. Omeros CEO Gregory Demopulos commented, "We’re pleased to have received agreement from FDA for our OMS721 Phase 3 protocol in IgA nephropathy [...] Final preparations to begin the trial can now be completed and enrollment is expected to open in early February.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Omeros Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Omeros Corp. – Pfizer Inc., BioTime, Inc., Acura Pharmaceuticals, Inc., Akorn, Inc., DURECT Corporation and Pain Therapeutics, Inc. (PFE-US, BTX-US, ACUR-US, AKRX-US, DRRX-US and PTIE-US) that have also reported ... Read more (Read more...)
Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.